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ARTICLE OPEN
Identifying possible asthma–COPD overlap syndrome in
patients with a new diagnosis of COPD in primary care
Camilla Boslev Baarnes1, Peter Kjeldgaard1, Mia Nielsen1, Marc Miravitlles2 and Charlotte Suppli Ulrik1,3
The asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) remains poorly characterised. Our aim was to
describe an algorithm for identifying possible ACOS in adults with newly diagnosed COPD in primary care. General practitioners
(n= 241) consecutively recruited subjects ⩾ 35 years, with tobacco exposure, at least one respiratory symptom and no previous
diagnosis of obstructive lung disease. Possible ACOS was deﬁned as chronic airﬂow obstruction, i.e., post-bronchodilator (BD)
forced expiratory volume 1/forced vital capacity (FEV1/FVC) ratioo0.70, combined with wheeze (ACOS wheeze) and/or signiﬁcant
BD reversibility (ACOS BD reversibility). Of 3,875 (50% females, mean age 57 years) subjects screened, 700 (18.1%) were diagnosed
with COPD, i.e., symptom(s), tobacco exposure and chronic airﬂow obstruction. Indications for ACOS were found in 264 (38%) of the
COPD patients. The prevalence of ACOS wheeze and ACOS BD reversibility was 27% (n= 190) and 16% (n= 113), respectively
(Po0.001), and only 6% (n= 39) of the COPD patients fulﬁlled both criteria for ACOS. Patients with any ACOS were younger
(P= 0.04), had more dyspnoea (Po0.001), lower FEV1%pred (67% vs. 74%; Po0.001) and lower FEV1/FVC ratio (P= 0.001) compared
with COPD-only patients. Comparing subjects fulﬁlling both criteria for ACOS with those fulﬁlling criteria for ACOS wheeze only
(n= 151) and those fulﬁlling criteria for ACOS BD reversibility only (n= 74) revealed no signiﬁcant differences. Irrespective of the
applied ACOS deﬁnition, no signiﬁcant difference in life-time tobacco exposure was found between ACOS- and COPD-only patients.
In subjects with a new diagnosis of COPD, the prevalence of ACOS is high. When screening for COPD in general practice among
patients with no previous diagnosis of obstructive lung disease, patients with possible ACOS may be identiﬁed by self-reported
wheeze and/or BD reversibility.
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INTRODUCTION
A signiﬁcant proportion of patients presenting with symptoms of
obstructive lung disease has features of both asthma and chronic
obstructive pulmonary disease (COPD),1,2 often referred to as the
asthma–COPD overlap syndrome (ACOS).3–5 In recent years, the
ACOS has gained much attention and been extensively
reviewed.3,5–9 However, so far there is no generally agreed term
or deﬁning features for this category of patients with chronic
airway obstruction,10 although diagnostic criteria have been
proposed based on consensus for overlap in patients already
diagnosed with COPD.4,11,12
The proportion of patients with ACOS among individuals with
existing COPD is unclear, as it depends very much on the applied
deﬁning criteria, but has been reported to be between 15 and
60%.13–15 Furthermore, concurrent doctor-diagnosed COPD and
asthma have been reported in up to 20% of patients with
obstructive lung disease.16,17 Given these uncertainties, it appears
important to establish useful and reliable criteria for identifying
patients with possible ACOS, i.e., an asthma component of their
disease, not least when these patients are diagnosed in primary care.
Pharmacological therapy of patients with asthma–COPD overlap
can at present not be evidence-based, as this group of patients
has, although together with a substantial proportion of all patients
with obstructive lung disease, consistently been excluded from
participating in clinical trials.1 So, as clinical trials have until now
only enrolled patients with the extreme phenotypes of both
asthma and COPD,18 there is a clear need for clinical trials to
establish evidence-based therapy for this group of patients.6
In the meantime, a number of national guidelines11,12,19 and
the GINA-GOLD ACOS document4 have attempted to establish
consensus-based treatment options for patients with ACOS.
However, as patients with asthma–COPD overlap seem to be at
risk for a poor outcome, including a high risk of exacerbations, it is
important to identify this subgroup of patients with COPD to
ensure adequate treatment of the asthma component of their
disease, including anti-inﬂammatory therapy, also for patients
diagnosed in primary care.
The aim of the present study was to describe an algorithm for
identifying possible ACOS in adults with newly diagnosed COPD
by applying different diagnostic criteria in a large cohort of
individuals at high risk of COPD, but no previous diagnosis of
obstructive lung disease, in a primary care setting to facilitate
identiﬁcation of patients with an asthma component of their
disease, as this subgroup of patients with COPD is likely to be at
risk for a poor outcome.
RESULTS
Description of cohort
Baseline characteristics of enrolled subjects. A total of 241 general
practitioners (GPs; ~ 7% of Danish GPs) participated in the study.
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Of the 4,049 screened subjects, 3,875 (95.7%; 50% males; mean
age 57 years (range 35–92 years)) fulﬁlled the inclusion criteria,
and were included in the present analysis. Of the enrolled
subjects, 2,390 (61.7%; no difference between males and females)
were current smokers (mean estimated life-time tobacco
exposure 34.5 pack-years) and 1,485 ex-smokers (38.3%, mean
28.5 pack-years; Table 1).
Prevalence of respiratory symptoms and airﬂow obstruction.
Cough was the most prevalent symptom among the enrolled
subjects, followed by dyspnoea and sputum production (Figure 1).
Of the 3,875 subjects enrolled in the study, 700 (18.1%)
fulﬁlled the criteria for chronic airﬂow obstruction, i.e., a post-
bronchodilator (BD) forced expiratory volume 1/forced vital
capacity (FEV1/FVC) ratioo0.70 (Table 1). Furthermore, 1.190
(30.7%) of the enrolled subjects had an FEV1o80%pred.
Subjects with self-reported wheeze (n= 710; 18.3%) had,
compared with participants not reporting wheeze, a signiﬁcant
higher prevalence of both chronic airﬂow obstruction (27.1% vs.
16.4%; Po0.001) and FEV1o80%pred (44.9% vs. 27.5%;
Po0.001).
Non-COPD participants
A total of 3,175 (77%) of the subjects had tobacco exposure and at
least one respiratory symptom, but no chronic airﬂow obstruction,
i.e., FEV1/FVC ratio40.70 either at the screening spirometry
(n= 2,963) or following the administration of BD (n= 212).
Of these 3,175 subjects, 718 (23%) had an FEV1o80%pred.
Participants with COPD
Of the 700 patients fulﬁlling the diagnostic criteria for COPD,
85% had, based on spirometric criteria, mild-to-moderate COPD
(Table 1). Patients diagnosed with COPD were older, had more
dyspnoea (Medical Research Council (MRC) score) and higher life-
time tobacco exposure (39.7 and 30.5 pack-years, respectively;
Po0.0001) compared with non-COPD participants (Table 1).
Any ACOS deﬁned as chronic airﬂow obstruction and wheeze and/or
a positive BD test compared with COPD only. The prevalence
of any ACOS among all screened subjects (n= 3,875) was 6.8%.
Any ACOS was found in 264 (37.8%) of the patients with a new
diagnosis of COPD (Figure 2).
Compared with patients with COPD only, patients with any
ACOS were characterised by being younger, having more
dyspnoea (MRC score), lower FEV1 and lower FEV1/FVC ratio
(Table 2), whereas no difference was found in life-time tobacco
exposure. In line with this, patients fulﬁlling both criteria for ACOS
were also younger (Po0.05), had more dyspnoea (P= 0.001),
lower FEV1 (P= 0.01) and lower FEV1/FVC ratio (Po0.001)
Table 1. Baseline characteristics of the enrolled subjects (n= 3,875),
including divided according to COPD status
All (n= 3,875) COPD (n= 700) No COPD (n= 3,175)
Age (years) 57.4 (11.8) 63.0 (10.5) 56.2 (11.7)a
BMI 27.0 (5.1) 25.8 (5.1) 27.2 (5.0)a
Pack-years 32.2 (22.3) 39.7 (23.2) 30.5 (21.8)a
FEV1 (l) 2.64 (0.88) 1.90 (0.69) 2.80 (0.83)
FEV1 (%pred.) 88.6 (19.6) 71.1 (19.1) 92.5 (17.5)
FEV1/FVC 0.75 (0.09) 0.61 (0.07) 0.79 (0.06)
MRC score 1.7 (0.7) 2.0 (0.8) 1.7 (0.7)a
Abbreviations: BMI, body mass index; COPD, chronic obstructive
pulmonary disease; FEV1/FVC, forced expiratory volume 1/forced vital
capacity; MCR, Medical Research Council.
aPo0.001 COPD versus no COPD.
Figure 1. Prevalence of respiratory symptoms among the enrolled
subjects (n= 3.875). LRTI, recurrent lower respiratory tract infections.
Figure 2. Flow chart of the 3,875 individuals at high risk of COPD,
but no previous diagnosis of obstructive lung disease, included in
the present analysis divided according to the presence or absence
of COPD, possible asthma–COPD overlap syndrome (ACOS) or COPD
only, respectively.
Table 2. Characteristics of the 700 patients with a new diagnosis of
COPD divided into participants with possible ACOS and COPD only
Any ACOS
(n=264)
COPD only
(n= 436)
P-value
Age (years) 61.9 (10.9) 63.6 (10.2) P= 0.04
BMI 26.2 (5.7) 25.5 (4.6) NS
Pack-years 39.9 (22.8) 39.5 (23.4) NS
FEV1 (l) 1.75 (0.67) 1.99 (0.68) Po0.001
FEV1 (%pred.) 66.6 (18.7) 73.8 (18.8) Po0.001
FEV1/FVC 0.60 (0.08) 0.62 (0.07) Po0.001
MRC score 2.2 (0.8) 1.8 (0.8) Po0.001
BD reversibility (l) 0.18 l (0.22) 0.03 (0.14) Po0.001
Abbreviations: ACOS, asthma–COPD overlap syndrome; BD, bronchodila-
tor; BMI, body mass index; COPD, chronic obstructive pulmonary disease;
FEV1/FVC, forced expiratory volume 1/forced vital capacity; MCR, Medical
Research Council.
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compared with COPD-only patients, but no difference in number
of pack-years (P= 0.75).
ACOS deﬁned as chronic airﬂow obstruction and wheeze (ACOS-W).
The prevalence of ACOS deﬁned as chronic airﬂow obstruction and
wheeze, i.e., ACOS-W, in the entire cohort was 5% (n=190)
corresponding to a prevalence of ACOS-W of 27.2% within the
group of subjects diagnosed with COPD (Table 3). Patients with
ACOS-W had, as assessed by the MRC score, more dyspnoea
(Po0.0001) compared with subjects with COPD not reporting
wheeze (n= 510).
Comparing patients with ACOS-W and COPD only showed that
the former subjects were younger (61.5 vs. 63.5 years; P= 0.02) and
had higher body mass index (26.8 vs. 25.4; Po0.01), lower post-
BD FEV1/FVC ratio (0.60 vs. 0.62; P= 0.02) and lower post-BD FEV1%
pred (65.7 (18.7) vs. 73.1 (18.9); Po0.0001), whereas no signiﬁcant
difference was found in life-time tobacco exposure (pack-years)
and absolute or percentage increase in FEV1 after administration
of BD.
ACOS deﬁned as chronic airﬂow obstruction and positive BD
reversibility test. One-hundred and thirteen subjects (3% of the
entire cohort) had chronic airﬂow obstruction and a positive
BD reversibility (BDR) test, i.e., ACOS-BDR. The prevalence of
ACOS-BDR was 16.2% among the patients diagnosed with COPD
(Table 3). No signiﬁcant difference was found in MRC score
between patients with COPD only and ACOS-BDR (P= 0.6).
Patients with ACOS-BDR had signiﬁcantly lower FEV1/FVC ratio
(0.59 vs. 0.61; P= 0.03) and, by deﬁnition, higher BDR (Po0.001)
compared with patients with COPD only, whereas no signiﬁcant
difference was found between the two groups in age, body mass
index, pack-years of smoking or FEV1%pred.
ACOS deﬁned as chronic airﬂow obstruction and wheeze and a
positive BD test compared with ACOS-W and ACOS-BDR only. A
total of 39 patients (5.6%) diagnosed with COPD fulﬁlled both
criteria for ACOS; 151 and 74 patients, respectively, only fulﬁlled
the ACOS wheeze and ACOS-BDR criteria (Figure 2). Subjects
fulﬁlling both criteria for ACOS had more dyspnoea compared
with both ACOS-W- and ACOS-BDR-only patients (Po0.01 for
both comparisons), but no differences were found between
the groups, i.e., ACOS-W+ACOS-BDR versus ACOS-W only and
ACOS-BDR only, with regard to age, number of pack-years, FEV1%
pred or FEV1/FVC ratio.
The prevalence of respiratory symptoms, other than wheeze,
in the groups of subjects classiﬁed as having possible ACOS
(as deﬁned above) compared with participants with no COPD and
COPD only is given in Figure 3. In general, patients with possible
ACOS had more symptoms than participants with no COPD and
COPD only, whereas no gender differences were found.
DISCUSSION
Main ﬁndings
In the present study, we investigated algorithms for identifying
possible ACOS in a large cohort of subjects at high risk of COPD
(prevalence of COPD 18.1%), but with no previous diagnosis of
obstructive lung disease, including asthma, aiming at facilitating
the identiﬁcation of COPD patients with an asthma component of
their disease.
Among the 700 (18.1% of the cohort) patients diagnosed with
COPD, the prevalence of ACOS varied between 5.6 and 27.2%
depending on the applied criteria. The combination of chronic
airﬂow obstruction and wheeze as criteria revealed the highest
prevalence of possible ACOS (27%), and compared with COPD
only, these patients had more dyspnoea and lower FEV1%pred,
whereas no difference was found in BDR. In contrast to this,
these differences were not found between patients with possible
ACOS- and COPD-only patients when ACOS was deﬁned on the
basis of BDR (ACOS-BDR). Patients with COPD fulﬁlling the applied
deﬁnition of ACOS, irrespective of the criteria, had signiﬁcantly
lower FEV1/FVC ratio compared with the COPD-only patients,
whereas no differences were found in life-time tobacco exposure
when comparing any ACOS and COPD only.
Interpretation of ﬁndings in relation to previously published work
No universal consensus exists on diagnosis of asthma–COPD
overlap,9,20 and we, therefore, based our classiﬁcation on elements
from the Global Initiative for Asthma and Global Initiative
for Chronic Obstructive Lung Disease document4 together with
criteria applied in previously published studies.21–23 Furthermore,
as our primary aim was to develop an algorithm for identifying
individuals with possible ACOS among patients with a new
Table 3. Characteristics of the 264 patients with possible ACOS, divided according to the presence of self-reported wheeze (ACOS wheeze) and/or a
positive bronchodilator reversibility test (ACOS BD reversibility)
ACOS wheeze and ACOS BD reversibility (n=39) ACOS wheeze (n=151) ACOS BD reversibility (n= 74)
Age (years) 60.4 (12.0) 61.5 (10.9) 62.2 (11.2)
BMI 25.3 (5.6) 26.8 (5.9) 25.0 (5.1)
Pack-years 38.4 (18.3) 40.4 (22.6) 38.5 (21.9)
FEV1 (l) 1.71 (0.70) 1.79 (0.67) 1.64 (0.68)
FEV1 (%pred.) 66.4 (16.4) 65.7 (18.7) 68.0 (17.9)
FEV1/FVC 0.57 (0.08) 0.60 (0.08) 0.59 (0.08)
MRC score 2.5 (1.1)a 2.3 (0.9)a 2.1 (0.9)a
Abbreviations: ACOS, asthma–COPD overlap syndrome; BD, bronchodilator; BMI, body mass index; COPD, chronic obstructive pulmonary disease;
FEV1/FVC, forced expiratory volume 1/forced vital capacity; MCR, Medical Research Council.
aPo0.01 for ACOS wheeze and BD reversibility compared with ACOS wheeze and ACOS BD reversibility.
Figure 3. Prevalence of respiratory symptoms among participants
with no COPD (n= 3.175), COPD only (n= 436) and possible
ACOS, identiﬁed by either self-reported wheeze (ACIS wheeze;
n= 151), bronchodilator reversibility (ACOS-BDR; n= 74) of both
(ACOS wheeze + BDR; n= 39).
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diagnosis of COPD in general practice, the applied criteria had to
be obtainable in that setting. Self-reported wheeze has been
shown to be far more prevalent among patients classiﬁed as
having asthma–COPD overlap compared with COPD only24 and
the BDR criteria has been recommended and applied in previous
studies.4,21,23,25
The average tobacco exposure was found to be 32 pack-years,
which is lower than that often reported from clinical trials of
patients with COPD,26,27 most likely due to the selection of
subjects with no previous diagnosis of obstructive lung disease;
and in keeping with previous studies, tobacco exposure was
higher, and level of lung function tended to be lower, in males
compared with that in females. Another important difference
between the present cohort and patients enrolled in COPD trials is
the high proportion of current smokers (62%) in our study, which
points to an important opportunity for guidance on smoking
cessation, also because the most common respiratory symptom
was cough, by many smokers regarded as a harmless smoking-
related symptom.
Of the enrolled subjects without chronic airﬂow obstruction
(n= 3,175), 23% had lung function impairment, i.e., FEV1o80%
pred that may suggest underlying respiratory disease other than
COPD, but, unfortunately, the present diagnostic algorithm did
not allow us to evaluate these individuals further.
The highest prevalence of possible ACOS was observed by
applying the deﬁnition of chronic airﬂow obstruction and wheeze.
Wheeze is caused by air passing through too narrow airways, and
may be caused by different disease processes, including asthma,
COPD and heart failure. Thus, this deﬁnition may, therefore, seem
too broad for identifying individuals with an overlap between
asthma and COPD. In keeping with this, patients classiﬁed into the
ACOS group by this deﬁnition had more dyspnoea compared
with the COPD-only group. Using the same criteria, although in a
cross-sectional population study, Chung et al.28 found a pre-
valence of ACOS of 2.3% in the total population, corresponding to
a prevalence of 30% in the COPD group, similar to the ﬁndings in
the present study. Furthermore, Huang et al.29 have recently
reported that the presence of episodic wheezing in patients with
COPD has a negative impact on morbidity.
Previously, studies have reported a prevalence of ACOS from 15
to 60% among patients with COPD.13–15 However, the criteria for
ACOS differs between studies,30 as some are based on symptoms
and spirometric parameters,28,31 others on the presence of a
physician’s diagnosis of both asthma and COPD,13,32–34 and some
on a mixture of these criteria.14,35
The present opportunistic screening study is, to our knowledge,
the ﬁrst to apply different deﬁnitions of ACOS in the same cohort
of individuals with newly diagnosed COPD, and by that
demonstrating a wide variation in proportion of patients who will
be classiﬁed as having ACOS among patients with COPD
depending on the applied diagnostic criteria. However, as the
patients enrolled in the present study had no previous diagnosis
of obstructive lung disease, direct comparisons with previous
studies are difﬁcult.5,35 However, in the study by Menezes et al.35
ACOS was deﬁned as a FEV1/FVCo0.7 plus wheezing in the
past 12 months plus BDR, revealing a prevalence of ACOS of 13%
(89 patients) among their 683 COPD patients, which is higher than
the 5.6% observed in our study. However, comparable to our
study, they found a higher degree of reversibility, but no
difference in estimated life-time tobacco exposure. Furthermore,
in contrast to our ﬁndings, their patients with ACOS were slightly
younger, had higher body mass index and lower FEV1 compared
with COPD-only patients, and experienced more dyspnoea.
Strengths and limitations of the study
As there is no gold standard for the diagnosis of ACOS,9,36 we
cannot be absolutely sure that newly diagnosed COPD patients
with BDR and/or self-reported wheezing always have ACOS, nor
that patients with these characteristics will be considered to have
ACOS by all examining physicians. The latter not least because it
has been recognised for years, and reported from large-scale
clinical trials, that patients with COPD may have reversibility
without being considered to have an asthma component of their
disease.37 However, in spite of that, the present study may provide
important knowledge with regard to identiﬁcation of patients with
possible ACOS among new patients diagnosed with COPD.
The majority of patients with COPD are diagnosed and
managed in primary care, and as wheezing and BDR are easy to
detect characteristics also in primary care,38 our ﬁndings may offer
substantial guidance for general practitioners to screen for
possible ACOS among their patients with COPD, although further
diagnostic work-up is likely to be needed. By this, our ﬁndings add
to a recent study showing that a previous diagnosis of asthma
may also be a reliable criterion for a probable diagnosis of ACOS.39
However, one of the main differences between the two studies is
that patients with a previous diagnosis of asthma were excluded
from the present study.
Implications for future research, policy and practice
The prevalence of possible ACOS was high in our subjects with a
new diagnosis of COPD (5.6–27.2%), irrespective of the applied
deﬁnition. Our ﬁndings, therefore, suggests a substantial
occurrence of ACOS among subjects with COPD identiﬁed by
opportunistic screening in general practice, which points to the
GP as a key person in identifying subjects with ACOS; not least
because these subjects are likely to have a high risk of
poor outcome, especially if they are not prescribed adequate
treatment for the asthma component of their disease, including
anti-inﬂammatory therapy.
The present observations are likely to have important
implications not only for management, including pharmacological
therapy, but also for outcome for patients with newly diagnosed
COPD. However, beforehand it seems of utmost importance to
reach consensus with regard to diagnostic criteria, as this is a
prerequisite for clinical trials of therapeutic options and, later, the
development of evidence-based guidelines for the management
for this group of patients.
Conclusions
The present study showed that a large proportion of subjects
with a new diagnosis of COPD, in the majority of cases
mild-to-moderate disease, can, irrespective of the applied criteria,
be classiﬁed as having probable ACOS.
MATERIALS AND METHODS
Study design
GPs all over Denmark were invited to take part, and the aim was to engage
at least 200 GPs (45% of Danish GPs) to obtain a representative sample.40
Each of the participating GPs was expected to assess at least 20
consecutive subjects who attended their practice for respiratory or
non-respiratory symptoms and fulﬁlled the criteria for participation in
the study (6-month study period). Subjects included had all study-related
procedures, including spirometry, performed in their own GPs practice
(by trained staff).
Material
Subjects were eligible for the study if they had no previous diagnosis of
obstructive lung disease (COPD and/or asthma, including a history of
early-onset asthma) provided they also fulﬁlled the following inclusion
criteria: (1) age ⩾ 35 years, (2) smoker/ex-smoker, (3) ⩾ 1 respiratory
symptom (dyspnoea, cough, wheeze, sputum and/or recurrent chest
infections); and not the following exclusion criteria: (1) unable to perform
spirometry.
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Methods
All participants ﬁlled in a questionnaire regarding age, gender, height,
body weight, smoking status (including daily tobacco consumption and
years of smoking), current airway symptoms (including cough, dyspnoea,
wheezing, sputum and recurrent lower airway infections) and severity of
dyspnoea (MRC scale).41 Spirometry was performed in accordance with the
guidelines from the Danish Respiratory Society,42 and included at least
three forced expiratory manoeuvres (and with the two highest measure-
ments of FEV1 and FVC, respectively, differing o5%).
Diagnostic algorithm
Airway obstruction was deﬁned as FEV1/FVC ratioo0.70, in accordance
with the GOLD strategy document.43 All participants with airway
obstruction at screening spirometry (i.e., pre-BD spirometry) had a BDR
test performed with 0.4 mg inhaled salbutamol (or equivalent) followed by
a spirometry 15 min after; and only participants with a post-BD
FEV1/FVCo0.70 were deﬁned as having airway obstruction. A positive
BD test was deﬁned as an increase in FEV1412% and 200 ml.
44
Deﬁnitions
COPD was diagnosed on the basis of current or previous tobacco exposure,
respiratory symptom(s) and post-BD FEV1/FVC ratioo0.70, in accordance
with the GOLD.44 Within the group of individuals diagnosed with COPD,
ACOS was deﬁned on the basis of criteria used in previous publications as
follows: (1) self-reported wheeze28,35 (ACOS-W) and/or (2) a positive BDR
test35 (ACOS-BDR).
Data handling and analysis
Questionnaires and spirometric data were recorded in a consolidated
web-based database. Derived values were automatically calculated by the
computer, including number of pack-years, body mass index, FEV1%
predicted and FEV1/FVC. Statistical analyses were performed with the
software SPSS v. 21.0 (IBM corporation, Armonk, NY, USA).
The analyses were limited to subjects with complete data. Data were
tested for normality, and non-parametric tests for independent samples
were used to analyse continuous data. Categorical data were analysed by
the Mann–Whitney U-test. In all the statistical analyses, a two-tailed P-value
of ⩽ 0.05 was considered signiﬁcant. Mean values are reported with s.d.
Groups of interest were compared based on the presence of airway
obstruction at screening spirometry, symptoms, MRC, COPD, ACOS
and BDR.
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